<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01383096</url>
  </required_header>
  <id_info>
    <org_study_id>MMV_OZ439_11_001</org_study_id>
    <nct_id>NCT01383096</nct_id>
  </id_info>
  <brief_title>Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers</brief_title>
  <official_title>A Phase I Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines for Malaria Venture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nucleus Network Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INC Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicines for Malaria Venture</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess prototype formulations compared to the aqueous dispersion of
      Active Pharmaceutical Ingredient used in Phase I and Phase IIa studies to date. It is hoped
      that the bioavailability of OZ439 can be enhanced in the fasted state to be close to that
      observed when given after food. This will improve the utility of OZ439 in the field as well
      as decreasing the cost of treatment (by decreasing the dose of OZ439 required) which is very
      important for an antimalarial drug product destined for use in developing counties.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a single centre, open-label, pharmacokinetic, randomized cross-over study in
      healthy male volunteers and post-menopausal women. This study was conducted over three
      different cohorts as follows:

      Cohort 1: Subjects received a single 800 mg (as free base) dose of five different treatment
      regimes (treatments A, B, C, D and E) on five occasions.

      Cohort 2: Subjects received a single 800 mg (as free base) dose of four different treatment
      regimes (treatments F, G, H and I) on four occasions.

      Cohort 3: Subjects received a single dose, 800mg (as free base) of prototype solution
      formulation 1 (treatment J) and 400mg (as free base) of prototype solution formulation 1
      (treatment K) on two occasions. The treatments were administered under the fasted state.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OZ439 Cmax</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing</time_frame>
    <description>The maximum observed plasma drug concentrations (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OZ439 AUC0-∞</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing</time_frame>
    <description>Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OZ439 t1/2</measure>
    <time_frame>1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing</time_frame>
    <description>Apparent terminal half life (t1/2)</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Treatment A: OZ439 800mg PIB, fed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>OZ439 800 mg (as free base) as powder in a bottle (PIB)for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Best Prototype Solution - OZ439 400 mg as prototype solution formulation 1. Administered fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Treatement B: OZ439 800mg PIB fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Treatment C:OZ439 800mg PIB with milk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Best Prototype Solution - OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Treatement F: OZ439 800 mg PIB fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Treatement G: OZ439 800mg PIB with milk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 mesylate 800mg Powder in Bottle for Oral Suspension</intervention_name>
    <description>OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration</description>
    <arm_group_label>Cohort 1 - Treatment A: OZ439 800mg PIB, fed</arm_group_label>
    <arm_group_label>Cohort 1 - Treatement B: OZ439 800mg PIB fasted</arm_group_label>
    <arm_group_label>Cohort 1 - Treatment C:OZ439 800mg PIB with milk</arm_group_label>
    <arm_group_label>Cohort 2 - Treatement F: OZ439 800 mg PIB fasted</arm_group_label>
    <arm_group_label>Cohort 2 - Treatement G: OZ439 800mg PIB with milk</arm_group_label>
    <other_name>OZ439 PIB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 mesylate 400mg Prototype Solution Formula 1</intervention_name>
    <description>OZ439 400 mg (as free base) as a prototype solution formulation 1</description>
    <arm_group_label>Cohort 3 - Treatement K: OZ439 400mg Prototype F1 fasted</arm_group_label>
    <other_name>OZ439 400mg Prototype 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 mesylate 800mg Prototype Solution Formula 1</intervention_name>
    <description>OZ439 800 mg (as free base) as a prototype solution formulation 1</description>
    <arm_group_label>Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 fasted</arm_group_label>
    <arm_group_label>Cohort 3 - Treatment J: OZ439 800mg Prototype F1 fasted</arm_group_label>
    <arm_group_label>Cohort 1 - Treatement E: OZ439 800mg Prototype F1 with milk</arm_group_label>
    <other_name>OZ439 800mg Prototype 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OZ439 mesylate 800mg Prototype Solution Formula 2</intervention_name>
    <description>OZ439 800 mg (as free base) as a prototype solution formulation 2</description>
    <arm_group_label>Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 fasted</arm_group_label>
    <arm_group_label>Cohort 2 - Treatement I: OZ349 800mg Prototype F2 with milk</arm_group_label>
    <other_name>OZ439 800mg Prototype 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers between 18 and 55 years (inclusive).
             Post-menopausal women with amenorrhoea for at least 2 years are eligible confirmed by
             FSH level &gt;/ = 25microlU/ml

          -  Body mass Index between 18 and 30 kg/m2, inclusive; and body weight &gt; 50 kg.

          -  Healthy as determined by pre-study medical history, physical examination (including
             body temperature), 12 Lead ECG.

          -  Male volunteers must agree to use a double barrier method of contraception including
             abstinence, condom plus diaphragm or condom plus IUD or condom plus stable
             oral/transdermal/injectable hormonal contraceptive by female partner for at least 14
             days prior to the time of the first dose of study drug through 90 days after the last
             dose of study drug and must also agree to not donate sperm for 90 days after the last
             dose of study drug. Vasectomy with zero sperm count for 6 months minimum prior to the
             first dose of study drug is an acceptable form of contraception

          -  Clinical laboratory tests at screening within the reference ranges or if outside the
             normal range not clinically significant. ALT, AST and total bilirubin must be within
             the normal range

          -  Able and willing to give written informed consent

          -  Willing and able to adhere to the lifestyle guideline requirements

          -  Willing and able to be confined to the Clinical Research Unit as required by the
             protocol

        Exclusion Criteria:

          -  Evidence of or history of clinically significant oncologic, pulmonary, hepatic,
             cardiovascular, hematologic, metabolic, neurological, immunologic, nephrologic,
             endocrine, psychiatric disease, or current infection

          -  Evidence of or history of clinically significant gastrointestinal (excluding
             appendectomy and cholecystectomy) disease or current infection.

          -  Any condition that could possibly affect drug absorption, e.g. gastrectomy, diarrhea

          -  History of post-antibiotic colitis

          -  Pregnancy or breastfeeding

          -  QTc greater than 450 msec for males and females as corrected by the Fredricia's
             formula or evidence or history of abnormal cardiac rhythm

          -  History of drug or alcohol abuse within the past 2 years prior to Screening

          -  Tobacco users (includes stopping smoking less than 90 days prior to screening.
             &quot;Tobacco use&quot; includes smoking and the use of snuff and chewing tobacco, and other
             nicotine containing products

          -  Received an investigational drug or participated in another research study within 30
             days of the first dose of study drug in any part of the study

          -  Use of prescription drugs within 14 days prior to the first dose of study drug in
             Period 1, or need for any antibiotic during the study

          -  Received any non prescription medications, vitamins, herbal supplements or dietary
             supplements within 7 days of the first dose of study drug in Period 1, unless prior
             approval is granted. Excluded from this list is intermittent use of acetaminophen at
             doses of up to 2 g/day

          -  Consumed alcohol within 72 hours of Day -1 in any part of the study, or have a
             positive alcohol screen at screening or each admission

          -  Consumed fruit juice or ate grapefruit within 7 days prior to the first dose of study
             drug in any part of the study

          -  Positive test for human immunodeficiency virus, hepatitis B surface antigen or
             anti-hepatitis C virus

          -  Positive urine drug screen at Screening or admission

          -  History of intolerance or hypersensitivity to artemisinins

          -  Likelihood of requiring treatment during the study period with drugs not permitted by
             the study protocol

          -  Volunteers who have donated blood or experienced significant blood loss within 90 days
             of screening

          -  Hemoglobin &lt; 13.5 g/dL for males and &lt; 12.5 g/dL for females

          -  Any concern by the investigator regarding the safe participation of the volunteer or
             any reason the investigator considers the volunteer inappropriate for participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Peter Hodsman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMREP Centre for Clinical Studies, Nucleus Network, 89 Commercial Road, Melbourne, VIC 3004 Australia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AMREP Centre for Clinical Studies</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>VIC 3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2011</study_first_posted>
  <results_first_submitted>May 12, 2014</results_first_submitted>
  <results_first_submitted_qc>January 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2015</results_first_posted>
  <last_update_submitted>January 19, 2015</last_update_submitted>
  <last_update_submitted_qc>January 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OZ439</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Food Effect</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was randomised on 19-Apr-12; The last subject last visit was on 04-Aug-12. Subjects were recruited at the study site, Nucleus Network.</recruitment_details>
      <pre_assignment_details>There was no wash-out, run-in or transition period between enrolment and group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Subjects received a single dose of OZ439 800mg PIB Fed, then OZ439 PIB Fasted, then OZ439 800mg with milk, OZ439 800mg Prototype 1 Fasted, OZ439 800mg Prototype 1 with milk.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Subjects received a single of OZ439 800mg PIB Fasted, then OZ439 800mg with milk, OZ439 800mg Prototype 2 Fasted, OZ439 800mg Prototype 2 with milk.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>Subjects received a 800mg single dose of OZ439 prototype solution formulation 1 fasted and then a 400mg single dose of OZ439 of prototype solution formulation 1 fasted.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Vomited Study Drug within 30min of admin</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Haemoglobin was &lt;13.5 g/dL</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0">Only 2 interventions in Cohort 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0">Only 2 interventions in Cohort 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Elevated AST</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vomited Study Drug within 30min of admin</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>QTcF was greater than 450 msec</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fourth Intervention (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0">Only 2 interventions in Cohort 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0">Only 2 interventions in Cohort 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Haemoglobin was &lt;13.5 g/dL</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>QTcF was greater than 450 msec</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Fifth Intervention (8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="0">Only 4 interventions in Cohort 2.</participants>
                <participants group_id="P3" count="0">Only 2 interventions in Cohort 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0">Only 4 interventions in Cohort 2.</participants>
                <participants group_id="P3" count="0">Only 2 interventions in Cohort 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>haemoglobin was &lt;13.5 g/dL</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety population was comprised of all randomized subjects who received any amount of study drug and was based on the actual treatment received at each time point, if this differed from that to which the subject was randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Subjects received a single dose of OZ439 800mg PIB Fed, then OZ439 PIB Fasted, then OZ439 800mg with milk, OZ439 800mg Prototype 1 Fasted, OZ439 800mg Prototype 1 with milk.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Subjects received a single dose of OZ439 800mg PIB Fasted, then OZ439 800mg with milk, OZ439 800mg Prototype 2 Fasted, OZ439 800mg Prototype 2 with milk.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Subjects received a 800mg single dose of OZ439 prototype solution formulation 1 fasted and then a 400mg single dose of OZ439 of prototype solution formulation 1 fasted.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="16"/>
            <count group_id="B4" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.3" spread="6.2"/>
                    <measurement group_id="B2" value="27.2" spread="5.7"/>
                    <measurement group_id="B3" value="25.4" spread="4.4"/>
                    <measurement group_id="B4" value="27.4" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>OZ439 Cmax</title>
        <description>The maximum observed plasma drug concentrations (Cmax)</description>
        <time_frame>1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing</time_frame>
        <population>Pharmacokinetic Population: all subjects who received study drug, and completed at least one treatment (provided they had adequate OZ439 plasma concentration data) were included in the pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Treatment A: OZ439 800mg PIB Fed</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Treatment B: OZ439 800mg PIB Fasted</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 - Treatment:OZ439 800mg PIB With Milk</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 Fasted</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 - Treatment E: OZ439 800mg Prototype F1 With Milk</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2 - Treatment F: OZ439 800 mg PIB Fasted</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2 - Treatment G: OZ439 800mg PIB With Milk</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 - Treatment H: OZ439 800 mg Prototype F2 Fasted</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 - Treatment I: OZ349 800mg Prototype F2 With Milk</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3 - Treatment J: OZ439 800mg Prototype F1 Fasted</title>
            <description>OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3 - Treatment K: OZ439 400mg Prototype F1 Fasted</title>
            <description>OZ439 400 mg as prototype solution formulation 1. Administered fasted.</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 Cmax</title>
          <description>The maximum observed plasma drug concentrations (Cmax)</description>
          <population>Pharmacokinetic Population: all subjects who received study drug, and completed at least one treatment (provided they had adequate OZ439 plasma concentration data) were included in the pharmacokinetic analysis.</population>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="14"/>
                <count group_id="O11" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1910" spread="32.9"/>
                    <measurement group_id="O2" value="827" spread="47.7"/>
                    <measurement group_id="O3" value="1930" spread="27.4"/>
                    <measurement group_id="O4" value="1440" spread="46.2"/>
                    <measurement group_id="O5" value="1830" spread="25.9"/>
                    <measurement group_id="O6" value="538" spread="33.2"/>
                    <measurement group_id="O7" value="1530" spread="31.2"/>
                    <measurement group_id="O8" value="846" spread="44.9"/>
                    <measurement group_id="O9" value="1680" spread="36.2"/>
                    <measurement group_id="O10" value="1160" spread="35.8"/>
                    <measurement group_id="O11" value="719" spread="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OZ439 AUC0-∞</title>
        <description>Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)</description>
        <time_frame>1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing</time_frame>
        <population>Pharmacokinetic Population: all subjects who received study drug, and completed at least one treatment (provided they had adequate OZ439 plasma concentration data) were included in the pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Treatement A: OZ439 800mg PIB Fed</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Treatement B: OZ439 800mg PIB Fasted</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 - Treatment C:OZ439 800mg PIB With Milk</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 - Treatement D: OZ439 800 mg Prototype F1 Fasted</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 - Treatement E: OZ439 800mg Prototype F1 With Milk</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2 - Treatement F: OZ439 800 mg PIB Fasted</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2 - Treatement G: OZ439 800mg PIB With Milk</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 - Treatement H: OZ439 800 mg Prototype F2 Fasted</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 - Treatement I: OZ349 800mg Prototype F2 With Milk</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3 - Treatement J: OZ439 800mg Prototype F1 Fasted</title>
            <description>OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3 - Treatement K: OZ439 400mg Prototype F1 Fasted</title>
            <description>OZ439 400 mg as prototype solution formulation 1. Administered fasted.</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 AUC0-∞</title>
          <description>Area under the plasma concentration-time curve from zero to infinity (AUC0-∞)</description>
          <population>Pharmacokinetic Population: all subjects who received study drug, and completed at least one treatment (provided they had adequate OZ439 plasma concentration data) were included in the pharmacokinetic analysis.</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="14"/>
                <count group_id="O11" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29200" spread="31.2"/>
                    <measurement group_id="O2" value="10700" spread="52.8"/>
                    <measurement group_id="O3" value="24500" spread="44.0"/>
                    <measurement group_id="O4" value="19000" spread="39.6"/>
                    <measurement group_id="O5" value="25800" spread="26.9"/>
                    <measurement group_id="O6" value="7460" spread="34.1"/>
                    <measurement group_id="O7" value="21600" spread="33.0"/>
                    <measurement group_id="O8" value="11700" spread="54.9"/>
                    <measurement group_id="O9" value="22900" spread="41.9"/>
                    <measurement group_id="O10" value="13800" spread="38.0"/>
                    <measurement group_id="O11" value="7410" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OZ439 t1/2</title>
        <description>Apparent terminal half life (t1/2)</description>
        <time_frame>1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing</time_frame>
        <population>Pharmacokinetic Population: all subjects who received study drug, and completed at least one treatment (provided they had adequate OZ439 plasma concentration data) were included in the pharmacokinetic analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Treatment A: OZ439 800mg PIB Fed</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Treatment B: OZ439 800mg PIB Fasted</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1 - Treatment C: OZ439 800mg PIB With Milk</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 Fasted</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 1 - Treatment E: OZ439 800mg Prototype F1 With Milk</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 2 - Treatment F: OZ439 800 mg PIB Fasted</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 2 - Treatment G: OZ439 800mg PIB With Milk</title>
            <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 2 - Treatment H: OZ439 800 mg Prototype F2 Fasted</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 2 - Treatment I: OZ349 800mg Prototype F2 With Milk</title>
            <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 3 - Treatment J: OZ439 800mg Prototype F1 Fasted</title>
            <description>OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 3 - Treatment K: OZ439 400mg Prototype F1 Fasted</title>
            <description>OZ439 400 mg as prototype solution formulation 1. Administered fasted.</description>
          </group>
        </group_list>
        <measure>
          <title>OZ439 t1/2</title>
          <description>Apparent terminal half life (t1/2)</description>
          <population>Pharmacokinetic Population: all subjects who received study drug, and completed at least one treatment (provided they had adequate OZ439 plasma concentration data) were included in the pharmacokinetic analysis.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="12"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="14"/>
                <count group_id="O11" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" spread="27.8"/>
                    <measurement group_id="O2" value="82.3" spread="46.9"/>
                    <measurement group_id="O3" value="70.5" spread="45.9"/>
                    <measurement group_id="O4" value="90.0" spread="26.0"/>
                    <measurement group_id="O5" value="79.8" spread="27.2"/>
                    <measurement group_id="O6" value="84.7" spread="27.3"/>
                    <measurement group_id="O7" value="79.3" spread="28.0"/>
                    <measurement group_id="O8" value="85.7" spread="22.0"/>
                    <measurement group_id="O9" value="70.6" spread="17.7"/>
                    <measurement group_id="O10" value="63.6" spread="14.7"/>
                    <measurement group_id="O11" value="91.1" spread="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event monitoring throughout the admission period.</time_frame>
      <desc>The Safety population was comprised of all randomised subjects who received any amount of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 - Treatment A: OZ439 800mg PIB Fed</title>
          <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to administration. Administered 30 minutes after a standard fatty breakfast.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 - Treatment B: OZ439 800mg PIB Fasted</title>
          <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1 - Treatment C: OZ439 800mg PIB With Milk</title>
          <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1 - Treatment D: OZ439 800 mg Prototype F1 Fasted</title>
          <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered fasted.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 1 - Treatment E: OZ439 800mg Prototype F1 With Milk</title>
          <description>OZ439 800 mg (as free base) as a prototype solution formulation 1. Administered with milk.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 2 - Treatment F: OZ439 800 mg PIB Fasted</title>
          <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered fasted.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 2 - Treatment G: OZ439 800mg PIB With Milk</title>
          <description>OZ439 800 mg (as free base) as powder in a bottle (PIB) for reconstitution in a suspension prior to oral administration. Administered following 200 mL milk.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 2 - Treatment H: OZ439 800 mg Prototype F2 Fasted</title>
          <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered fasted.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 2 - Treatment I: OZ349 800mg Prototype F2 With Milk</title>
          <description>OZ439 800 mg (as free base) as a prototype solution formulation 2. Administered with milk.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 3 - Treatment J: OZ439 800mg Prototype F1 Fasted</title>
          <description>OZ439 800 mg (as free base) as prototype solution formulation 1. Administered fasted.</description>
        </group>
        <group group_id="E11">
          <title>Cohort 3 - Treatment K: OZ439 400mg Prototype F1 Fasted</title>
          <description>OZ439 400 mg as prototype solution formulation 1. Administered fasted.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="14"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure orthostatic decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Sleep paralysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Hodsman</name_or_title>
      <organization>Nucleus Network</organization>
      <phone>+ 613 9076 8900</phone>
      <email>businessdevelopment@nucleusnetwork.com.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

